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Abstract SLCO2B1, also known as OATP2B1 (Organic
Anion Transporter) or OATP-B or SLC21A9, is an organic
anion uptake transporter that is encoded by the SLCO2B1
gene. In this study we assessed the frequencies of
SLCO2B1 polymorphisms in a Korean population using
newly developed pyrosequencing methods and compared
their frequencies with those in other ethnic groups. We
developed pyrosequencing methods to identify the fol-
lowing six SLCO2B1 non-synonymous polymorphisms:
c.1175C [ T (rs1621378), c.1457C [ T (rs2306168),
c.43C [ T (rs56837383), c.935G [ A (rs12422149),
c.601G [ A (rs35199625) and c.644A [ T (rs72559740).
The allele frequencies of these polymorphisms were ana-
lyzed in 227 Korean subjects. The allele frequencies of
SLCO2B1 polymorphisms in the population tested were as
follows: 0.0 for c.1175C [ T, c.43C [ T and c.644A [ T;
0.2687 for c.1457C [ T; 0.4273 for c.935G [ A; and
0.0727 for c. 601G [ A. Even though the allele frequen-
cies of the c.1175C [ T and c.1457C [ T polymorphisms
were comparable to those in Japanese subjects, the fre-
quencies in this Korean population differed from those in
other ethnic groups. The developed pyrosequencing
methods are rapid and reliable for detecting non-synony-
mous SLCO2B1 polymorphisms. Large ethnic differences
in the frequency of SLCO2B1 genetic polymorphisms were
noted among ethnic groups. The SLCO2B1 polymorphisms
at c.1175C [ T, c.43C [ T and c.644A [ T were not
found in the Korean population while c.1457C [ T,
c.935G [ A and c.601G [ A exhibited mostly higher
frequencies in Koreans compared with Finnish, Caucasian
and African-American populations.
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Introduction
It has recently been recognized that drug pharmacokinetics,
efficacy and toxicity are related to the role of drug trans-
porters [1]. Solute Carrier Organic Anion Transporter 2B1
(SLCO2B1), also known as SLC21A9, OATP2B1 and
OATP-B, encodes a member of the organic anion trans-
porting polypeptide family of membrane proteins. The
SLCO2B1 transporter is expressed at the sinusoidal mem-
brane of hepatocytes in the liver, but also in other tissues
including the intestines and heart [2–4]. The SLCO2B1
transporter modulates the levels of endogenous substrates
including dehydroepiandrosterone-3-sulfate, estrone-3-sul-
fate and prostaglandin E2 [3–6]. In addition, it acts as a
transporter of various therapeutic drugs including mont-
elukast, cyclosporine, fexofenadine, and celiprolol [7–10].
Several polymorphisms have been identified in the
SLCO2B1 gene, and their frequencies are reported in dif-
ferent ethnic groups. Literature review shows that Nozawa
et al. [11] first reported the allele frequencies of SLCO2B1
gene, i.e., SLCO2B1*2 (c.1175C [ T) and SLCO2B1*3
(c.1457C [ T) in a Japanese population. Although there
have been subsequent studies reporting the frequencies of
SLCO2B1 polymorphisms in different populations, there is
still a limited amount of information available regarding
ethnic differences in SLCO2B1 genetic polymorphisms.
Functionally, the SLCO2B1 c.1457C [ T variant was
associated with a reduced activity in an in vitro study [11],
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and the c.601G [ A polymorphism has been associated
with markedly reduced transport activity in vitro [12].
Additionally, it was presented that the c.935G [ A poly-
morphism is associated with a significant reduction of
SLCO2B1 activity in vitro and in vivo [8]. Considering that
membrane transporters are important modulators of drug
disposition [13], it has been established that genetic poly-
morphisms in genes encoding these transporters may
account for inter-individual variability in the pharmacoki-
netics and pharmacodynamics of drugs.
However, the genetics and functional consequences of
SLCO2B1 variants have not been well characterized.
Therefore, we analyzed non-synonymous SNPs of the
SLCO2B1 gene using pyrosequencing methods. Previous
genetic analyses of SLCO2B1 variants were conducted
either by PCR–RFLP or real-time PCR [1, 8, 11]. Py-
rosequencing is a non-electrophoretic, real-time DNA
sequencing technology [14]. It involves the hybridization
of a primer to a single-stranded PCR template, and initia-
tion of the sequencing analysis by addition of nucleotides.
The nucleotides are added sequentially, and through cou-
pled enzymatic reactions, the polymerase-catalyzed incor-
poration of nucleotides can be monitored as light peaks in a
pyrogram. Pyrosequencing is consistent, easy to use, eco-
nomically viable, and allows for the generation of high
throughput analysis with a very high success rate [15].
In this study, we developed pyrosequencing methods
that can detect non-synonymous SNPs of SLCO2B1 poly-
morphisms. Using this technique, we assessed the allelic
frequencies of SLCO2B1 polymorphisms in a Korean
population, and compared these allelic frequencies to those
reported for other ethnic groups.
Materials and methods
Subjects and methods
Genomic DNA samples were obtained from 227 unrelated
male and female Korean subjects and written and informed
consent was obtained. The protocol for SLCO2B1 DNA
analyses was approved by the ethical committee of Anam
Hospital, Korea University College of Medicine, Seoul,
Korea.
Pyrosequencing method for detection of SLCO2B1
polymorphisms
Genomic DNA was isolated from peripheral leukocytes, as
described previously [16, 17]. We developed the pyrose-
quencing method to identify the following non-synonymous
SNPs of the SLCO2B1 gene: c.1175C [ T (rs1621378),
c.1457C [ T (rs2306168), c.43C [ T (rs56837383),
c.935G [ A (rs12422149) c.601G [ A (rs35199625) and
c.644A [ T (rs72559740) (Table 1). The primers used for
the PCR reaction for SLCO2B1 genotyping and pyrose-
quencing are described in Table 2. PCR reactions were car-
ried out to amplify sequences to identify each SLCO2B1 SNP
using newly developed primer sets after attaching biotin to
the 50 end of each forward (or reverse) primer using PSQ
Assay Design software (Pyrosequencing AB, Uppsala,
Sweden). The DNA fragments containing SLCO2B1 poly-
morphic sites were amplified using newly developed primer
sets after attaching biotin to the 50 end of each forward (or
reverse) primer using PSQ Assay Design software (Pyrose-
quencing AB, Uppsala, Sweden). PCR was performed in a
reaction volume of 30 ll containing genomic DNA (30 ng),
10 9 PCR buffer, dNTPs (0.25 mM), 10 pmol primers (1 ll
each) and 5U Taq polymerase (iNtRON, Seongnam, Korea).
PCR reactions were carried out with an initial denaturation
step of 94 C for 3 min, followed by 40 cycles of denatur-
ation at 94 C for 30 s, annealing at 58–63 C for 30 s and
extension at 72 C for 30 s. A final termination step was
performed at 72 C for 5 min (Table 2).
For pyrosequencing reactions, 25 ll of the PCR tem-
plate in a single well was immobilized by incubation (with
shaking at 1,400 rpm, 10 min, room temperature) with a
mixture of 5 ll streptavidin beads (Streptavidin Sephar-
oseTM High Performance, GE Healthcare Bio-Science AB,
Sweden) and 40 ll binding buffer. For primer annealing,
40 ll annealing buffer containing 0.4 lM sequencing pri-
mer was incorporated into each well. For strand separation,
all liquid was removed by a Vacuum Prep Workstation
(Pyrosequencing AB, Uppsala, Sweden). The beads cap-
tured on probes were incubated in 70 % ethanol and the
solution was flushed through the filters for 5 s. The beads
were then treated with a denaturing solution (0.2 M NaOH)
that was flushed through the filters for 5 s. A wash buffer
(10 mM Tris–acetate, pH 7.6) was used to rinse the beads
for 5 s. All liquid was completely drained from the probes,
and then the beads were released into a PSQ 96 Plate Low
(Pyrosequencing AB, Uppsala, Sweden) containing the
sequencing primer. The PSQ 96 Plate Low was heated at
85 C for 2 min, and the reactions were allowed to cool to
room temperature. The resulting mixture was analyzed on a
PSQ 96MA Pyrosequencer (Pyrosequencing AB, Uppsala,
Sweden). The accuracy of pyrosequencing was validated
by direct DNA sequencing for the randomly selected
samples using the same genomic DNA.
Statistical analysis
Genetic equilibrium and linkage disequilibrium were
assessed according to the Hardy–Weinberg formula using
SNPalyzer ver 7.0 (DYNACOM Co., Ltd, Yokohama,
Japan).
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Results
We identified each SNP for c.1175C [ T and c.1457C [ T
using a singlet pyrosequencing method, but multiplex py-
rosequencing methods were applied to identify the
c.43C [ T and c.935G [ A or c.601G [ A and
c.644A [ T SNPs simultaneously. Representative pre-
dicted histogram patterns for each genotype are presented
in Fig. 1. The assay was designed to generate a specific
sequence for each SNP by setting a suitable nucleotide
addition order. Nucleotide sequences and pyrograms
obtained for each SNP were consistent with the predicted
histograms (Fig. 2). The sequencing data obtained from the
pyrosequencing method was validated by direct DNA
sequencing of each SNP for randomly selected samples,
and the results showed 100 % concordance with the mul-
tiplex pyrosequencing results, indicating 100 % specificity
and sensitivity for the newly developed method.
When we analyzed the six non-synonymous SLCO2B1
genetic polymorphisms with the newly developed method in
227 unrelated Korean subjects, the observed allele frequencies
of SLCO2B1 polymorphisms were as follows: 0.0 for
c.1175C [ T, c.43C [ T and c.644A [ T, 0.2687 for
c.1457C [ T, 0.4273 for c.933G [ A, and 0.0727 for c.601G
[ A (Table 3). The allele frequency of c.935G [ A in the
population tested met Hardy–Weinberg equilibrium (v2 =
0.2795, P = 0.597 for c.935G[ A and v2 = 0.0877, P =
0.767 for c.601G [ A) whereas c.1457C [ T were not in
Hardy–Weinberg equilibrium (v2 = 4.2559, P = 0.0391).
When we compared the allele frequencies of SLCO2B1
polymorphisms in this population with those in other ethnic
groups, the c.1457C [ T polymorphism frequency were
found to be similar to those reported for a Japanese population,
but differed from those of other ethnic groups including
Caucasians and African-Americans (Table 4).
Discussion
In this study, we developed a rapid and robust pyrose-
quencing method to detect six non-synonymous SLCO2B1
SNPs and applied this technique to identify these SNPs in a
Korean population. We observed that there were substantial
differences in allele frequencies of SLCO2B1 genotypes
between our Korean sample and other ethnic groups.






SLCO2B1*2 (c.1175C [ T) rs1621378 Exon 9 Thr392Ile
SLCO2B1*3 (c.1457C [ T) rs2306168 Exon 10 Ser486Phe
c.935G [ A rs12422149 Exon 7 Gln312Arg
c.43C [ T rs56837383 Exon 2 Pro15Ser
c.601G [ A rs35199625 Exon 5 Met201Val
c.644A [ T rs72559740 Exon 5 Val215Asp
Table 2 Oligonucleotide
primers used for PCR and
pyrosequencing to detect
SLCO2B1 polymorphisms
B = biotinylated at the 50-end
of the primer
SNP Primer Sequences Size (bp) PCR (Tm; C)
c.43C [ T Forward 50-CTTGGTTCTGAGGTCTAGG-30 166 58
Reverse B 50-CCTCCAGGTGTGTTTTCT-30
Sequencing 50-GCGGGTGAGGTACCCCAG-30
c.601G [ A Forward 50-AACCCAGCATCTGAGTGT-30 145 58
Reverse B 50-GTCCTCACCGAGGTAGAG-30
Sequencing 50-CACAGACCCTGCTGGGC-30
c.644A [ T Forward 50-AACCCAGCATCTGAGTGT-30 145 58
Reverse B 50-GTCCTCACCGAGGTAGAG-30
Sequencing 50-TTTGGCATCTCCTACAT-30
c.935G [ A Forward B 50-CCCCTACTTCTTCTTCCC-30 115 58
Reverse 50-GACATGGAGGGAGCTTAC-30
Sequencing 50-TGTGACTGCTAAGACCTTT-30
c.1175C [ T Forward 50-GTAGGAGGCTGTGATGGA-30 88 58
Reverse B 50-CCAGGTATGCTTGTCATC-30
Sequencing 50-CCAGGAACTTGGGCAGG-30
c.1457C [ T Forward 50- ACCCTACTGGTCTTCTCTC-30 141 63
Reverse B 50-TGGCAGGGTGTGATGTATT-30
Sequencing 50-CCCACCCTGGGCTGGA-30
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To our knowledge, this is the first study to identify
SLCO2B1 polymorphisms using a pyrosequencing method.
Previously, SLCO2B1 SNPs were detected through PCR–
RFLP [7, 11, 18] and real-time PCR [1, 8].
SLCO2B1 is expressed in the liver, spleen, placenta,
lungs, kidneys, heart, ovaries, small intestine, and brain [19].
A number of endogenous and exogenous compounds act as
substrates of the SLCO2B1 transporter [6, 13]. A number of
studies have shown that SLCO2B1 SNPs could cause a
functional change in SLCO2B1 transport activity. Nozawa
and his colleague first reported the role of polymorphic
SLCO2B1 genes in modulating the expression levels of
OATP2B1 proteins in vitro [11]. The protein expression for
SLCO2B1*2 (c.1157C [ T) and SCLO2B1*3 (c.1457C [ T)
was 71.1 and 42.5 % compared with SLCO2B1*1 (wild type),
respectively [11]. Furthermore, c.1457C [ T exhibited
decreased transport activity in HEK cells [20]. It has consis-
tently been reported that subjects with the c.1457TT poly-
morphism exhibit 36 % lower AUC values but 52 % higher
oral clearance values for fexofenadine compared with those
with c.1457CC [7]. Asthma patients with the SNP positioned
at c.935G [ A exhibited a significant reduction in plasma
levels of montelukast and reduced permeability to the drug in a
MDCKII cell line expressing OATP2B1 [8]. Considering
these findings, we believe that genetic polymorphisms of
SLCO2B1 play a substantial role in modulation of the phar-
macokinetics/pharmacodynamics of SLCO2B1 substrates in
humans.
Among the genotypes we screened in this population,
we did not find any genetic substitution at c.1175C [ T,
c.43C [ T or c.644A [ T. We attempted to determine
whether there is an ethnic difference frequencies of these
alleles, but were only able to find one study reporting the
frequency of c.1175C [ T. Consistent with the present
study, this polymorphism was not observed in a Japanese
population [11], suggesting that the frequency of the
c.1157C [ T polymorphism is relatively low and may play
a minor role in Asian populations.
Other polymorphisms tested at c.1457C [ T,
c.935C [ T and c.601G [ A exhibited large differences in
Fig. 1 Pyrosequencing histograms for SLCO2B1 SNPs predicted by
pyrosequencing software. Shaded areas represent polymorphic sites
to be interrogated. a SLCO2B1*2 (c.1175C [ T), b SLCO2B1*3
(c.1457C [ T), c multiplex c.43C [ T/c.935G [ A and d multiplex
c.601G [ A/c.644A [ T
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allele frequencies among ethnic groups. The frequencies of
c.1457C [ T and c.601G [ A in a Finnish population were
2.8 and 2.1 %, respectively [1], while we observed fre-
quencies of 26.9 and 7.3 % for these two polymorphisms,
respectively, in our Korean sample. Considering the allele
frequency of c.1457C [ T was 30.9 % in a Japanese
population [20], there seems to be large ethnic variability
in the frequencies of SLCO2B1 polymorphisms.
Intriguingly, the occurrence of the c.935G [ A poly-
morphism was less than 15 % in Finnish (13.60 %), Afri-
can-American (13.16 %) and Caucasian (8.18 %)
populations, but we observed a 42.73 % allele frequency in
our Korean participants. Among the six non-synonymous
polymorphisms tested in this study, the c.935G [ A SNP
showed the highest polymorphic frequency, and this was
also the case in other ethnic groups. Even though the
results are controversial [21], previous studies revealed that
Fig. 2 Representative
pyrosequencing pyrograms for
a SLCO2B1*2 (c.1175C [ T),
b SLCO2B1*3 (c.1457C [ T),
c multiplex c.43C [ T/
c.935G [ A and d multiplex
c.601G [ A/c.644A [ T of the
SLCO2B1 gene
Table 3 Genotyping and allele frequencies of SLCO2B1 polymor-
phisms in this study
SNP Genotype No. Frequencies Allele Frequencies
c.1175C [ T G/G 227 1.0000 G 1.000
c.1457C [ T C/C 128 0.5639 C 0.7313
C/T 76 0.3348 T 0.2687
T/T 23 0.1013
c.43C [ T C/C 227 1.0000 C 1.000
c.933G [ A G/G 72 0.3172 G 0.5272
G/A 116 0.5110 A 0.4273
A/A 39 0.1718
c.601G [ A G/G 195 0.8590 G 0.9272
G/A 31 0.1336 A 0.0727
A/A 1 0.0004
c.644A [ T A/A 227 1.0000 A 1.000
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the c.935G [ A polymorphism influences the pharmaco-
kinetics and pharmacodynamics of montelukast, a
SLCO2B1 substrate, in humans. A comparison between
patients with c.935GG and c.935GA exhibited substantial
difference in montelukast concentrations and its efficacy
[8, 22], suggests that those with 935AA might be affected
more deleteriously in terms of montelukast treatment.
Considering the large ethnic differences in SLCO2B1
polymorphisms observed in the current study and the evi-
dence showing the modulating effect of SLCO2B1 on their
substrates’ plasma levels and efficacy [7, 8, 18], more
studies are warranted to validate the role of genetic vari-
ation of SLCO2B1 in the pharmacokinetics and pharma-
codynamics of SLCO2B1 substrates.
Conclusion
The developed pyrosequencing method is a rapid and
reliable genotyping method to detect six non-synonymous
SLCO2B1 polymorphisms. A large difference in SLCO2B1
genetic polymorphisms was noted when comparing our
Korean sample with other ethnic groups. The SLCO2B1
polymorphisms at c.1175C [ T, c.43C [ T and c.644A [
T were not found in our Korean population, but c.1457C
[ T, c.935G [ A and c.601G [ A exhibited higher fre-
quencies in Koreans population than in Finnish, Caucasian
and African-American populations.
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